Back to results
US 2025/0154274 A1Published application
Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
AssigneesBristol-Myers Squibb Company, Celldex Therapeutics, Inc.
InventorsVladimir CORIC, Tibor KELER, Thomas DAVIS
Life of this patent
Estimating the term…
Abstract
This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
Claims20
A method for treating a subject afflicted with a tumor comprising administering the subject in need thereof
- an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity (“anti-PD-1 antibody or antigen-binding portion thereof”) in combination with
- an antibody or an antigen-binding portion thereof that specifically binds to CD27 (“anti-CD27 antibody or antigen-binding portion thereof”).
Dependencies are inferred from the claim text.